Equillium Inc (EQ) - Total Assets
Based on the latest financial reports, Equillium Inc (EQ) holds total assets worth $34.51 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Equillium Inc for net asset value and shareholders' equity analysis.
Equillium Inc - Total Assets Trend (2017–2024)
This chart illustrates how Equillium Inc's total assets have evolved over time, based on quarterly financial data.
Equillium Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Equillium Inc's total assets of $34.51 Million consist of 97.6% current assets and 2.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 70.6% |
| Accounts Receivable | $1.14 Million | 4.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Equillium Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see EQ market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Equillium Inc's current assets represent 97.6% of total assets in 2024, a decrease from 100.0% in 2017.
- Cash Position: Cash and equivalents constituted 70.6% of total assets in 2024, down from 99.3% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 4.5% of total assets.
Equillium Inc Competitors by Total Assets
Key competitors of Equillium Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Equillium Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.85 | 3.04 | 11.79 |
| Quick Ratio | 10.85 | 3.04 | 11.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $30.48 Million | $22.59 Million | $78.18 Million |
Equillium Inc - Advanced Valuation Insights
This section examines the relationship between Equillium Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.92 |
| Latest Market Cap to Assets Ratio | 4.92 |
| Asset Growth Rate (YoY) | -49.3% |
| Total Assets | $25.60 Million |
| Market Capitalization | $126.05 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Equillium Inc's assets at a significant premium (4.92x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Equillium Inc's assets decreased by 49.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Equillium Inc (2017–2024)
The table below shows the annual total assets of Equillium Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $25.60 Million | -49.33% |
| 2023-12-31 | $50.53 Million | -35.57% |
| 2022-12-31 | $78.42 Million | -8.18% |
| 2021-12-31 | $85.41 Million | -0.03% |
| 2020-12-31 | $85.43 Million | +53.82% |
| 2019-12-31 | $55.54 Million | -17.31% |
| 2018-12-31 | $67.16 Million | +839.15% |
| 2017-12-31 | $7.15 Million | -- |
About Equillium Inc
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as we… Read more